Mizuho Said Adaptimmune Therapeutics plc (ADAP) ASCO Data 'Incrementally Supportive'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/6/2026
- S&P 500 struggles for direction as investors await Mideast deal; software stocks slide
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Sandisk unveils underwhelming outlook despite AI demand surge; shares slip
- Alphabet taps bond market with sweeping 10-part offering to fuel AI ambitions
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- Salesforce president Srini Tallapragada steps down, becomes advisor
- Sandisk (SNDK) Tops Q4 EPS by $4.66, Offers Guidance
- EverCommerce names Alex Goor as new CEO, founder steps down
- Crude Inventory Rose 2.5 Million Barrels Last Week - EIA
- AMD shares slide 8% after Musk flags plans to buy Nvidia chips for SpaceX
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
Adaptimmune Therapeutics (ADAP) Prices 20.5M ADS Offering at $11/ADS
June 2, 2020 5:52 AM EDTAdaptimmune Therapeutics plc (NASDAQ: ADAP) today announced the pricing of an underwritten public offering of 20,500,000 of its American Depositary Shares (ADSs) at a price to the public of $11.00 per ADS. In connection with the offering, Adaptimmune has granted the underwriters a 30-day option to purchase... More
Adaptimmune Therapeutics (ADAP) Announces Proposed 12.5M ADS Offering
June 1, 2020 6:12 AM EDTAdaptimmune Therapeutics plc (NASDAQ: ADAP) today announced that it intends to offer and sell 12,500,000 American Depositary Shares (ADSs) in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the... More
Adaptimmune (ADAP) Announces SPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in Esophagogastric Junction, Lung, and Head and Neck Cancers
May 29, 2020 7:33 AM EDTAdaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented updated data from its ADP-A2M4 Phase 1 trial at the American Society for Clinical Oncology (ASCO) Annual Meeting. The data demonstrate durability and responses in synovial sarcoma, supporting SPEARHEAD-1 as a potential registrational trial. The ASCO presentation also describes a new response in a patient with lung cancer, and a response in a patient with head and neck cancer (reported in January).
The Company also announced new responses in the SURPASS trial, confirming the potential for... More
